- Home
- SLGL vs PASG Comparison
SLGL vs PASG Comparison
Compare SLGL & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- PASG
- Stock Information
- Founded
- SLGL 1997
- PASG 2017
- Country
- SLGL Israel
- PASG United States
- Employees
- SLGL N/A
- PASG N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- PASG Health Care
- Exchange
- SLGL Nasdaq
- PASG Nasdaq
- Market Cap
- SLGL 19.3M
- PASG 20.3M
- IPO Year
- SLGL 2018
- PASG 2020
- Fundamental
- Price
- SLGL $8.14
- PASG $0.41
- Analyst Decision
- SLGL Buy
- PASG Strong Buy
- Analyst Count
- SLGL 1
- PASG 3
- Target Price
- SLGL $40.00
- PASG $7.67
- AVG Volume (30 Days)
- SLGL 25.4K
- PASG 376.4K
- Earning Date
- SLGL 08-15-2025
- PASG 08-07-2025
- Dividend Yield
- SLGL N/A
- PASG N/A
- EPS Growth
- SLGL N/A
- PASG N/A
- EPS
- SLGL N/A
- PASG N/A
- Revenue
- SLGL $12,103,000.00
- PASG N/A
- Revenue This Year
- SLGL N/A
- PASG N/A
- Revenue Next Year
- SLGL $31.17
- PASG N/A
- P/E Ratio
- SLGL N/A
- PASG N/A
- Revenue Growth
- SLGL 603.66
- PASG N/A
- 52 Week Low
- SLGL $3.34
- PASG $0.26
- 52 Week High
- SLGL $16.50
- PASG $1.33
- Technical
- Relative Strength Index (RSI)
- SLGL 63.80
- PASG 50.18
- Support Level
- SLGL $6.96
- PASG $0.40
- Resistance Level
- SLGL $7.48
- PASG $0.49
- Average True Range (ATR)
- SLGL 0.28
- PASG 0.05
- MACD
- SLGL 0.07
- PASG 0.00
- Stochastic Oscillator
- SLGL 95.88
- PASG 45.32
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.